By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SomaLogic said Tuesday that it has signed a multi-year research agreement with Novartis, under which the drug firm will use SomaLogics' proteomics technology to accelerate its drug discovery and development efforts.

Larry Gold, CEO of Boulder, Colo.-based SomaLogic, said in a statement that the alliance will help Novartis "define robust biomarkers, validate novel drug targets, and even develop companion clinical diagnostics."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.